Clinical Trials Browser

Phase 4 × Sunitinib × Clear all

Carcinoma, Renal Cell

NCT05949424 2023-11-29

OPTI-DOSE

Phase 4 Unknown

30 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Carcinoma, Renal Cell, Ovarian Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms

NCT02691793 2022-06-15

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Phase 4 Completed

1 enrolled

Other solid neoplasm

Refractory Solid Tumors

NCT01525550 2019-07-30

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Phase 4 Completed

106 enrolled 26 charts

EndocrineGastrointestinalNET

Adenoma, Carcinoma, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Phase 4 Completed

54 enrolled

GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

NCT00793871 2015-11-20

GIST

Phase 4 Completed

60 enrolled 14 charts

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00930345 2015-04-01

PREINSUT

Phase 4 Terminated

33 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00706706 2013-01-18

MRCC RCC

Phase 4 Completed

105 enrolled 9 charts

Genitourinary

Carcinoma, Renal Cell

Clinical Trials

SUP-R

OPTI-DOSE

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

GIST

PREINSUT

MRCC RCC